@article{
author = "Savić, Kristina and Zafirović, Sonja and Resanović, Ivana and Sudar, Emina and Maravić-Stojković, Vera and Putniković, Biljana and Isenović, Esma R.",
year = "2013",
abstract = "Biomarkeri predstavljaju indikatore normalnih bioloških procesa, patogenih procesa ili farmakoloških odgovora na terapijske intervencije. Interleukin-6 (IL6, engl. Interleukin-6) je biomarker, čija sinteza može biti aktivirana različitim stimulusima, kao što su: interferon-g (IFN-g, engl. Interferon-g), faktor tumorske nekroze (TNF, engl. Tumor Necrosis Factor) i/ili interleukin-1 (IL-1, engl. Interleukin-1). IL-6 svoje efekte ostvaruje preko IL-6 receptora (IL-6R, engl. IL-6 Receptor). Pokazano je da kod transgenih miševa, kod kojih je indukovana ekspresija IL-6 i IL-6R, dolazi do hipertrofije miokarda. U mehanizmu hipertrofije miokarda bitnu ulogu ima i novootkriveni kardiotrofin1 (CT-1, engl. Cardiotrophin-1) koji je jedan od članova IL-6 familije. Aktivnost IL-6 vezuje se za razvoj aneurizme abdominalne aorte (AAA, engl. Abdominal Aortic Aneurysm), zapravo, pokazano je da su aneurizme mesta odakle cirkuliše IL-6, a takođe se smatra da je koncentracija IL-6 u pozitivnoj korelaciji sa dijametrim AAA. C-reaktivni protein (CRP, engl. CReactive Protein) je jedan od mnogobrojnih biomarkera kardiovaskularnih bolesti. Uloga CRP-a je u nastanku i progresiji kardiovaskularnih bolesti. Lokalna produkcija CRP-a od strane glatkih mišićnih i endotelnih ćelija krvnog suda, u velikoj meri utiče na razvoj procesa ateroskleroze. Važnu ulogu u nastanku ateroskleroze, osim CRP-a, ima i oksidovani lipoprotein male gustine (ox-LDL, engl. Oxidized Low Density Lipoprotein). Oksidaciju LDL-a vrše različiti enzimi. Ox-LDL nakon što prođe u intimu krvnog suda indukuje sakupljanje monocita, tj. monociti se prevode u makrofage koji vezuju ox-LDL. Kada se makrofagi napune ox-LDL-om, dolazi do pokretanja signala ćelijske smrti i stvaraju se forme penušavih ćelija koje čine početni deo aterosklerotičnog plaka. Nova saznanja o mehamizmu delovanja kao i uloge biomerkera u nastanku kardiovaskularnih bolesti, svakako će pružiti jednu od mogućnosti prevencije nastanka ovih poremećaja, a takođe i adekvatnu terapiju u lecenju kardiovaskularnih oboljenja, što i jeste jedan od glavnih ciljeva intezivnih istraživanja u oblasti biomarkera. U ovom preglednom članku, opisana su tri biomarkera kardiovaskularnih bolesti: IL-6, CRP i LDL., Biomarkers are indicators of normal biological processes, pathogenic processes or pharmacologic responses to therapeutic interventions. Interleukin-6 (IL - 6) is a biomarker whose synthesis could be activated by various stimuli, such as interferon-g (IFN - g), tumor necrosis factor (TNF) and/or interleukin - 1 (IL - 1). IL - 6 achieves its effects through the IL-6 receptor (IL - 6R). It has been shown that transgenic mice, which have induced expression of IL - 6 and IL - 6R develop myocardial hypertrophy. In myocardial hypertrophy, an important role is played by a newly discovered cardiotrophin-1, a member of the IL - 6 family. The activity of IL - 6 is associated with the development of abdominal aortic aneurysm (AAA); in fact, it has been shown that the concentration of IL - 6 positively correlates with AAA diameters. C-reactive protein (CRP) is one of the biomarkers of cardiovascular diseases. Local production of CRP by the smooth muscular and endothelial cells of the vessel leads to the development of atherosclerosis to a large extent. Oxidized low-density lipoprotein (ox - LDL) also has an important role in the development of atherosclerosis. After penetrating the intima of the vessel, ox - LDL induces monocyte collection, i.e. monocytes are translated into macrophages that bind ox - LDL. Having filled the macrophages with ox - LDL, the signals of cell death are activated, which leads to the creation of foamy cells that make up the initial part of the atherosclerotic plaque. New knowledge about the mechanism of action and the role of biomarkers in the development of cardiovascular diseases will certainly provide an opportunity to prevent the onset of these disorders, as well as an adequate therapy in the treatment of cardiovascular diseases, which is one of the main goals of intensive research in the field of biomarkers.",
journal = "Medicinska istraživanja",
title = "Biomarkeri u kardiovaskularnim bolestima, Biomarkers of cardiovascular diseases",
volume = "47",
number = "2",
pages = "11-19",
doi = "10.5937/MedIst1302011S"
}
